Janus-kinase inhibitors in rheumatology

Tarasenko T.M.¹, Rekalov D.G.², Tarasenko O.N.¹, Docenko S.Ya.³, Shevchenko M.V.³, Svystun S.I.³

• ¹Kherson State University
• ²State Institution «National scientific center «Institute of Cardiology named after academician M.D. Strazhesko» National Academy of Medical Sciences of Ukraine, Kyiv
• ³Zaporizhia State Medical and Pharmaceutical University

Summary. Janus kinase inhibitors (JAKi) belong to one of the newest classes of targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) and have demonstrated high efficacy in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and other immune-mediated inflammatory diseases. JAKi’s mechanism of action is intracellular disruption of the JAK/STAT pathway, which is critical in the immune response. The convenience of oral JAKi, as opposed to biologics that require parenteral injections, is innovative from a patient perspective. This review discusses the efficacy and safety of JAKi in rheumatic diseases.